ceftriaxon fresenius kabi 1 g
fresenius kabi norge as - halden - ceftriaksonnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g
ceftriaxon mip 2 g
mip pharma gmbh - ceftriaksonnatrium - pulver til infusjonsvæske, oppløsning - 2 g
ceftriaxon mip 1 g
mip pharma gmbh - ceftriaksonnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g
ceftriaxon stragen 2 g
stragen nordic a/s - ceftriaksonnatrium - pulver til infusjonsvæske, oppløsning - 2 g
natriumklorid-glucos baxter viaflo 9 mg/ ml / 50 mg/ ml
baxter as - natriumklorid / glukose - infusjonsvæske, oppløsning - 9 mg/ ml / 50 mg/ ml
ondansetron accord 2 mg/ ml
accord healthcare b.v. - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml
ondansetron fresenius kabi 2 mg/ ml
fresenius kabi norge as - halden - ondansetronhydrokloriddihydrat - injeksjonsvæske, oppløsning - 2 mg/ ml
sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
plasmalyte glucos
baxter medical ab - glukosemonohydrat / natriumklorid / kaliumklorid / magnesiumkloridheksahydrat / natriumacetattrihydrat / natriumglukonat - infusjonsvæske, oppløsning - 50 mg/ ml / 5.26 mg/ ml / 0.37 mg/ ml / 0.3 mg/ ml / 3.68 mg/ ml / 5.02 mg/ ml
ondansetron kalceks 2 mg/ ml
as kalceks - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml